In vitro testing for Respiratory Sensitizers using a genomic biomarker signature and the GARD™ technology platform
A seminar given on two occasions, this one targeted for the EUROPEAN time zone
The presentation will give insight into the latest in vitro technology for identifying respiratory sensitizers using human dendritic-like cell lines and genomics. A thorough explanation of the GARD™ platform will be covered as well as its versatility and reliability for safety assessment applicable to all industries. Sensitization testing with GARD™ is based on functional genomics.
The presentation will cover:
- Development of the genomic-based GARD™ test platform for skin sensitization hazard, potency classification, and now also respiratory sensitization.
- Dendritic cells – why they are also relevant for respiratory sensitization.
- Gene mapping – what genes are in the assay, and how are they relevant for sensitization.
- How GARD™ can discriminate between skin and respiratory sensitization and why this is relevant.
Update on the development of the SenzaGen R&D pipeline including GARD™ for materials – testing medical devices, GARD™ for proteins – classification of protein sensitizers, GARD™ for mixtures – assessment of complex formulations and Unknown or Variable Composition UVCBs.
Next generation in vitro skin and respiratory sensitization testing using genomics with GARD™
The GARD™ platform is a versatile in vitro testing strategy which currently consist of three assays targeting two toxicological endpoints: skin sensitization (GARDskin & GARDpotency) and respiratory sensitization (GARDair). These assays make use of unique genomic biomarker signatures comprising genes involved in pathways known to be immunologically relevant to the sensitization process. Supported by modern technologies for pattern recognition, the large informational content provided by this approach enable for mechanism-of-action based decisions, which becomes evident in a consistently high predictive accuracy.
Don’t miss the opportunity to learn more from our researchers. Welcome to join!
